# Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

> **NCT04857359** · PHASE2,PHASE3 · TERMINATED · sponsor: **Addex Pharma S.A.** · enrollment: 25 (actual)

## Conditions studied

- Parkinson Disease
- Dyskinesia, Drug-Induced
- Dyskinesias

## Interventions

- **DRUG:** Dipraglurant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04857359
- **Lead sponsor:** Addex Pharma S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-06
- **Primary completion:** 2022-06-17
- **Final completion:** 2022-08-15
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Terminated prior to completing enrollment goals due to COVID-related difficulties in recruiting patients
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04857359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04857359, "Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04857359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*